Troy Anderson, MD
Internal Medicine · Wake Forest, NCNPI 1760430144
Payments from drug & device makers
Across 287 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$856
- Lilly USA, LLC$577
- Boehringer Ingelheim$333
- Amgen$329
- AbbVie$326
- AstraZeneca$274
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,732100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $856 |
| Lilly USA, LLC | 33 | $577 |
| Boehringer Ingelheim | 18 | $333 |
| Amgen(2 entities) | 23 | $329 |
| AbbVie(2 entities) | 20 | $326 |
| AstraZeneca | 19 | $274 |
| Pfizer | 16 | $233 |
| GSK | 9 | $160 |
| Astellas Pharma US Inc | 7 | $153 |
| Abbott | 6 | $151 |
| Amarin Pharma, Inc. | 10 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $101 |
| Johnson & Johnson | 6 | $97 |
| Exact Sciences | 4 | $88 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Jazz Pharmaceuticals Inc. | 5 | $75 |
| Eisai Inc. | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Bayer | 3 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Merck | 4 | $51 |
| Sanofi Pasteur Inc. | 3 | $44 |
| Adlon Therapeutics L.p. | 3 | $41 |
| Bausch Health US, LLC | 2 | $40 |
| Therapeuticsmd, Inc. | 3 | $36 |
| Antares Pharma, Inc. | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $31 |
| Boston Scientific | 1 | $25 |
| Medtronic | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Zealand Pharma US, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$4,732 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 143 | $154,523 |
| TrulicityDulaglutide | 60 | $73,689 |
| JanuviaSitagliptin Phosphate | 39 | $54,764 |
| OzempicSemaglutide | 28 | $40,349 |
| RybelsusSemaglutide | 15 | $27,228 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $26,287 |
| XareltoRivaroxaban | 32 | $25,321 |
| EliquisApixaban | 25 | $17,771 |
| MounjaroTirzepatide | 16 | $17,516 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $16,486 |
| MyrbetriqMirabegron | 14 | $16,005 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $15,761 |
| Victoza 3-PakLiraglutide | 12 | $12,920 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $12,508 |
| Saxagliptin-Metformin ErSaxagliptin Hcl/Metformin Hcl | 16 | $7,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $333 | $180,810163 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $577 | $91,20576 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $856 | $84,06457 claims |
| MerckJanuvia, Janumet | $51 | $70,52554 claims |
| Johnson & JohnsonXarelto | $97 | $25,32132 claims |
| PfizerEliquis, Paxlovid | $233 | $20,62936 claims |
| Astellas Pharma US IncMyrbetriq | $153 | $16,00514 claims |
| GSKBreo Ellipta | $160 | $12,50813 claims |
| AbbVieSynthroid | $326 | $4,54847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Wake Forest
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.